About the Authors
- Daniel J. Hogan
-
Affiliation Regulus Therapeutics, San Diego, California, United States of America
- Thomas M. Vincent
-
Affiliation Regulus Therapeutics, San Diego, California, United States of America
- Sarah Fish
-
Affiliation Regulus Therapeutics, San Diego, California, United States of America
- Eric G. Marcusson
-
Affiliation Regulus Therapeutics, San Diego, California, United States of America
- Balkrishen Bhat
-
Affiliation Regulus Therapeutics, San Diego, California, United States of America
- B. Nelson Chau
-
* E-mail: nchau@regulusrx.com (BNC); dzisoulis@regulusrx.com (DGZ)
Affiliation Regulus Therapeutics, San Diego, California, United States of America
- Dimitrios G. Zisoulis
-
* E-mail: nchau@regulusrx.com (BNC); dzisoulis@regulusrx.com (DGZ)
Affiliation Regulus Therapeutics, San Diego, California, United States of America
Competing Interests
Regulus Therapeutics Inc. has approved or pending patents involving miRNA technology. More specifically, Regulus holds exclusive rights to patents covering miR-122 anti-miRs and their application in inhibiting HCV replication and miR-21 anti-miRs and their use as cancer and fibrosis therapeutics (U.S. Patents No. 7,232,806, No. 7,307,067, No. 7,582,744 and No. 7,683,036). This does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: DGZ DJH EGM BNC. Performed the experiments: DJH DGZ TMV SF. Analyzed the data: DJH DGZ TMV SF. Contributed reagents/materials/analysis tools: BB. Wrote the paper: DGZ DJH EGM BNC.